VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

VistaGen Therapeutics reports Q1 loss, focuses on FDA approval

VistaGen Therapeutics faces financial challenges with increased expenses but shows strength in its innovative drug candidates targeting mental health disorders. The company's opportunities lie in FDA approval for fasedienol and market expansion for its pherine drug candidates.

VistaGen reports positive trial results and financial stability in Q2

VistaGen Therapeutics showcased positive trial results and financial stability, emphasizing the potential of their pherine pipeline to create value and improve lives.
While facing challenges such as increased expenses and operational concerns, the company's commitment to advancing treatments presents opportunities for growth and market expansion.
Analyst interest in study details and timelines reflects investor confidence in VistaGen's research programs and potential market impact.
Overall, VistaGen's Q2 performance highlights progress in lead programs and a solid financial foundation for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35.

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Julian Pino - Stifel Andrew Tsai - Jefferies Myles Minter - William Blair Madison El-Saadi - B. Riley Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call.

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. “We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute t.

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic.

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update.

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to succeed in supporting a filing for marketing approval. VTGN had $108.4M as of June 30, 2024, but increased R&D expenses may accelerate cash burn, and the Company could look to use its at-the-market facility or conduct an offering.

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know

SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on Oc.

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in U.S. registration-directed Phase 3 development for.

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Madison Elsaadi - B. Riley Securities Operator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago.

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, and provided a corporate update. “Building on the success of our PALISADE-2 Phase 3 trial of fasedienol,.

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 first quarter en.

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Bitfarms Ltd

SoFi Technologies

Lately, the stock market has been soaring thanks mostly to growth stocks trading at sky-high valuations. While rate cuts could potentially boost markets, caution is still warranted for most investors.

3 Stocks Under $15 That Could Make You a Millionaire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is a non-systemic, hormone.

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace. Vistagen's suppor.

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2024 Earnings Conference Call June 11, 2024 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Operator Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update. “Vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. Most notably, with.

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fis.

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in New York City. Jefferies Global Healthcare Conference Shawn Singh, Chief Executive Of.

Vistagen to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2.

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

Blade Air Mobility

SoundHound AI Inc

Penny stocks can be super volatile, but the potential of a modest investment ballooning into a multi-bagger is tough to pass up. These stocks represent the riskier end of the public equity range.

3 Must-Have Penny Stocks to Boost Your 2024 Portfolio

Digital Ally Inc

Mullen Automotive

The hype train is always talking about meme stocks set for a rebound on Reddit (NASDAQ: RDDT ). I try my best to avoid these large echo chambers of misinformation.

News for VistaGen Therapeutics Stock (VTGN)